EGFR and non-small cell lung carcinoma: In summary, this study observed and analyzed the efficacy and safety of osimertinib combined with anlotinib in three or more lines of treatment of 34 patients with advanced NSCLC who harbored T90M mutations after resistance to first‐ or second‐generation EGFR‐TKI.